ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Company profile
Ticker
CDXC
Exchange
Website
CEO
Mr. Robert N. Fried
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
CODY RESOURCES, INC.
SEC CIK
Corporate docs
Subsidiaries
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number
262940963
CDXC stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
11 Oct 24
8-K
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
20 Sep 24
8-K
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
7 Aug 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Departure of Directors or Certain Officers
16 Jul 24
8-K
Departure of Directors or Certain Officers
25 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 24
8-K
ChromaDex Corporation Reports First Quarter 2024 Financial Results
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
Transcripts
CDXC
Earnings call transcript
2024 Q2
7 Aug 24
CDXC
Earnings call transcript
2024 Q1
8 May 24
CDXC
Earnings call transcript
2023 Q4
6 Mar 24
CDXC
Earnings call transcript
2023 Q3
8 Nov 23
CDXC
Earnings call transcript
2023 Q2
9 Aug 23
CDXC
Earnings call transcript
2023 Q2
9 Aug 23
CDXC
Earnings call transcript
2023 Q1
10 May 23
CDXC
Earnings call transcript
2022 Q4
8 Mar 23
CDXC
Earnings call transcript
2022 Q3
2 Nov 22
CDXC
Earnings call transcript
2022 Q2
11 Aug 22
Latest ownership filings
4
Kristin Patrick
26 Aug 24
144
Notice of proposed sale of securities
23 Aug 24
4
Ka Shing Li
21 Aug 24
4
Hoi Shuen Solina Holly Chau
21 Aug 24
SC 13D/A
Pioneer Step Holdings Ltd
21 Aug 24
SC 13D/A
Prime Tech Global Ltd
21 Aug 24
3
Jeong James Lee
26 Jul 24
4
Steven D Rubin
24 Jun 24
4
Kristin Patrick
24 Jun 24
4
Wang Yu Gary Ng
24 Jun 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.89 mm | 27.89 mm | 27.89 mm | 27.89 mm | 27.89 mm | 27.89 mm |
Cash burn (monthly) | (no burn) | (no burn) | 85.33 k | 191.83 k | 88.00 k | (no burn) |
Cash used (since last report) | n/a | n/a | 301.20 k | 677.11 k | 310.61 k | n/a |
Cash remaining | n/a | n/a | 27.58 mm | 27.21 mm | 27.57 mm | n/a |
Runway (months of cash) | n/a | n/a | 323.2 | 141.8 | 313.3 | n/a |
Institutional ownership, Q2 2024
69.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 68 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 36.45 bn |
Total shares | 52.36 mm |
Total puts | 18.90 k |
Total calls | 91.70 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Champion River Ventures | 7.94 mm | $12.31 mm |
Pioneer Step | 6.92 mm | $8.51 mm |
Shing Li Ka | 6.50 mm | $11.44 mm |
Hoi Shuen Solina Holly Chau | 5.96 mm | $38.73 mm |
Societe des Produits Nestle | 3.82 mm | $5.53 mm |
Li Ka Shing | 3.47 mm | $12.97 mm |
Vanguard | 3.39 mm | $9.24 bn |
BLK BlackRock | 3.12 mm | $8.51 bn |
Tieton Capital Management | 2.97 mm | $8.10 mm |
ICONIQ Capital | 1.30 mm | $3.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Aug 24 | Kristin Patrick | Common Stock | Sell | Dispose S | No | No | 3.57 | 23,000 | 82.11 k | 0 |
23 Aug 24 | Kristin Patrick | Common Stock | Option exercise | Acquire M | No | No | 1.67 | 20,000 | 33.40 k | 23,000 |
23 Aug 24 | Kristin Patrick | Common Stock | Option exercise | Acquire M | No | No | 1.64 | 3,000 | 4.92 k | 3,000 |
23 Aug 24 | Kristin Patrick | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.67 | 20,000 | 33.40 k | 0 |
23 Aug 24 | Kristin Patrick | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.64 | 3,000 | 4.92 k | 17,000 |
20 Jun 24 | Ann Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 2.71 | 20,000 | 54.20 k | 20,000 |
20 Jun 24 | Frank L Jaksch Jr | Stock Option Common Stock | Grant | Acquire A | No | No | 2.71 | 20,000 | 54.20 k | 20,000 |
20 Jun 24 | Hamed Shahbazi | Stock Option Common Stock | Grant | Acquire A | No | No | 2.71 | 20,000 | 54.20 k | 20,000 |
News
HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target
9 Aug 24
ChromaDex Now Expects FY24 Revenue Growth Of 10% - 15% Y/Y
7 Aug 24
ChromaDex Q2 Sales $22.739M Miss $23.437M Estimate
7 Aug 24
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners
23 Jul 24
Press releases
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
15 Oct 24
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
26 Sep 24
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
20 Sep 24
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
10 Sep 24
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
9 Sep 24